Genomics And Pharmacogenomics In Anticancer Drug Development And Clinical Response (Cancer Drug Discovery And Development)

Size: px
Start display at page:

Download "Genomics And Pharmacogenomics In Anticancer Drug Development And Clinical Response (Cancer Drug Discovery And Development)"

Transcription

1 Genomics And Pharmacogenomics In Anticancer Drug Development And Clinical Response (Cancer Drug Discovery And Development)

2 Strategies for modern biomarker and drug - Oct 3, 2014 Sequencing the cancer genome is a vital component to understanding the to assess for early signals of clinical response, with the assessment of various biomarkers Historically, clinical trials in drug development have employed a The discovery and evaluation of any novel biomarkers will ideally be

3 Genome Medicine Full text Pharmacogenomics of - This review focuses on the contribution of germline genetic variation to chemotherapeutic toxicity Genetics and Pharmacogenomics of Anticancer Pharmacogenetics and Pharmacogenomics of - Pharmacogenetics and Pharmacogenomics of Anticancer Agents. [Pharmacogenomics. 2004] Review Genetics and smoking behavior. Clin Adv Hematol Oncol Sep; 5 REVIEW: Pharmacogenomic Frontiers in Medicine and - The novel genomic information to be used in tackling disease may be viewed as In addition, pharmacogenomics can speed up drug development by Most prominent among these complications has involved the anti-cancer drugs thioguanine patient response and speeding up the rate of drug development and clinical Pharmacogenomics on anti-cancer drugs: research - Pharmacogenomics on anti-cancer drugs: research advances: LIU Jing-tao, JIAO Yuan-yuan, ZHANG Yan-hua (Ministry of Education, Key laboratory of Carcinogenesis and Genomics And Pharmacogenomics In Anticancer Drug - Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response (Cancer Drug Discovery and Development) Author: Federico Innocenti Clinical Pharmacogenomics: Premarket Evaluation -. in new drug development in evaluating how variations in the human genome, begins with discovery and continues through confirmation of clinical efficacy and. titration intervals, based on genetic effects on drug exposure, dose-response, early. Pharmacogenetics and pharmacogenomics: a bridge to - To have a better understanding of the relationship between human genetics pharmacogenetics and pharmacogenomics anti-cancer drugs

4 Pharmacogenetics and pharmacogenomics: a bridge - These drugs are commonly indicated in the treatments of cancers, and cardiovascular, Second, unique to anticancer treatment, two related but different genomic heritability analysis among 29 FDA-approved anti-cancer drugs using a total of scientific discovery into clinical practice and in new drug development. Download Genomics and Pharmacogenomics in - Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response, Federico Innocenti, Springer, 2008, , , 392 pages. Anticancer Drug Discovery: Role of - Department of New Drug Discovery Research, Ranbaxy Laboratories human subjects regulate biological response playing important role in cancer pathophysiology stages of clinical development. 5 understanding of genome. Pharmacogenomics the key to developing - It has the potential to optimise both drug development and drug therapy which can predict the clinical response to the monoclonal antibody trastuzumab. Also, in cancer therapeutics, there is a constant influx of novel targeted anticancer drugs Pharmacogenomics, through the use of genomicbased testing, could Federico Innocenti (Author of Genomics and - Federico Innocenti is the author of Pharmacogenomics (0.0 avg rating, 0 ratings, 0 reviews, published 2013), Methods in Molecular Biology, Volume 311 (0. Pharmacogenetics and pharmacogenomics of - M. J. (2009), Pharmacogenetics and pharmacogenomics of anticancer agents. CA: A Cancer Journal for Clinicians, 59: Pharmacogenetics and Genomics,

5 Genomics and pharmacogenomics in anticancer drug - Genre/Form: Electronic books: Additional Physical Format: Print version: Genomics and pharmacogenomics in anticancer drug development and clinical response. Genomics and Pharmacogenomics in Anticancer Drug - In "Pharmacogenomics, Anticancer Drug Discovery, and Response," edited by Federico the role of genomic information in cancer therapy and in drug development and clinical examples of the application of genomic medicine in oncology. Frontiers Clinical practice guidelines for - The development of clinical guidelines for implementing pharmacogenomics knowledge in anticancer therapy is still at an early stage. Although Table 1 shows over 40 The Pharmacogenetics Research Network: From SNP - SNP Discovery to Clinical Drug Response ing basic principles of drug therapy and development.. genome that contain genetic variants associated with a CANCER. Pharmacogenetics of Anticancer Agents Research. Introduction. Pharmacogenetics - Wikipedia, the free - Pharmacogenetics is the study of because the therapeutic window of most anticancer drugs is narrow The Pharmacogenetics and Pharmacogenomics Drug Discovery and Development Journals - - Drug discovery & development: Genomics, bioinformatics & beyond Journals See also Journals Molecular Medicine Pharmacogenomics Toxicogenomics Reports both clinical and experimental results related to anti- cancer drugs, and Research on factors affecting the disposition of the clinical response to drugs, and Cancer Pharmacogenomics: Powerful Tools in - - Explain how genetic factors contribute to variability in drug response. soon be applied to clinical practice and clinical trials of currently prescribed anticancer drugs of pharmacogenomics in clinical cancer therapy and cancer drug development.. Genomic DNA can be extracted from the buffy coat fraction of whole blood

Genomics And Pharmacogenomics In Anticancer Drug Development And Clinical Response (Cancer Drug Discovery And Development) READ ONLINE

Genomics And Pharmacogenomics In Anticancer Drug Development And Clinical Response (Cancer Drug Discovery And Development) READ ONLINE Genomics And Pharmacogenomics In Anticancer Drug Development And Clinical Response (Cancer Drug Discovery And Development) READ ONLINE to modify patients' exposure to drugs based on their genomic drug-response

More information

Bayer Pharma s High Tech Platform integrates technology experts worldwide establishing one of the leading drug discovery research platforms

Bayer Pharma s High Tech Platform integrates technology experts worldwide establishing one of the leading drug discovery research platforms Bayer Pharma s High Tech Platform integrates technology experts worldwide establishing one of the leading drug discovery research platforms Genomics Bioinformatics HTS Combinatorial chemistry Protein drugs

More information

Single Nucleotide Polymorphisms: Methods And Protocols (Methods In Molecular Biology)

Single Nucleotide Polymorphisms: Methods And Protocols (Methods In Molecular Biology) Single Nucleotide Polymorphisms: Methods And Protocols (Methods In Molecular Biology) If you are looking for a ebook Single Nucleotide Polymorphisms: Methods and Protocols (Methods in Molecular Biology)

More information

Issues in Cancer Drug Development of the Future. Janet Woodcock M.D. Deputy Commissioner/Chief Medical Officer, FDA October 5, 2007

Issues in Cancer Drug Development of the Future. Janet Woodcock M.D. Deputy Commissioner/Chief Medical Officer, FDA October 5, 2007 Issues in Cancer Drug Development of the Future Janet Woodcock M.D. Deputy Commissioner/Chief Medical Officer, FDA October 5, 2007 Agenda: Scientific Issues n Why improve the quality of cancer clinical

More information

A new strategy for genetics & pharmacogenomics (GpGx) Robert M. Plenge, MD, PhD Vice President Head of Genetics & Pharmacogenomics

A new strategy for genetics & pharmacogenomics (GpGx) Robert M. Plenge, MD, PhD Vice President Head of Genetics & Pharmacogenomics A new strategy for genetics & pharmacogenomics (GpGx) Robert M. Plenge, MD, PhD Vice President Head of Genetics & Pharmacogenomics 1 Robert Plenge Our Shared Goals Impact the entire pipeline Drive early

More information

Pharmacogenetics: A SNPshot of the Future. Ani Khondkaryan Genomics, Bioinformatics, and Medicine Spring 2001

Pharmacogenetics: A SNPshot of the Future. Ani Khondkaryan Genomics, Bioinformatics, and Medicine Spring 2001 Pharmacogenetics: A SNPshot of the Future Ani Khondkaryan Genomics, Bioinformatics, and Medicine Spring 2001 1 I. What is pharmacogenetics? It is the study of how genetic variation affects drug response

More information

The Irish Biomarker Network - Inaugural Workshop Improved Translation of Biomarkers to the Clinic

The Irish Biomarker Network - Inaugural Workshop Improved Translation of Biomarkers to the Clinic The Irish Biomarker Network - Inaugural Workshop Improved Translation of Biomarkers to the Clinic 1 The Irish Biomarker Network -Inaugural Workshop Improved Translation of Biomarkers to the Clinic Overview

More information

Each revolutionary change in

Each revolutionary change in The Art and Science of Personalized Medicine M Piquette-Miller and DM Grant If it were not for the great variability among individuals, medicine might as well be a science and not an art. Sir William Osler,

More information

Adis Journals and Newsletters The premier collection of drug-focused medical journals

Adis Journals and Newsletters The premier collection of drug-focused medical journals adis.com Adis Journals and Newsletters The premier collection of drug-focused medical journals An invaluable resource for all involved in medical research, practice or teaching, drug regulation or reimbursement,

More information

Introduction to clinical trials Magnus Kjaer

Introduction to clinical trials Magnus Kjaer Introduction to clinical trials 2016-01-20 Magnus Kjaer One Definition of Clinical Trial NIH 2014 A research study in which one or more human subjects are prospectively assigned to one or more interventions

More information

Frumkin, 2e Part 1: Methods and Paradigms. Chapter 6: Genetics and Environmental Health

Frumkin, 2e Part 1: Methods and Paradigms. Chapter 6: Genetics and Environmental Health Frumkin, 2e Part 1: Methods and Paradigms Chapter 6: Genetics and Environmental Health Genetics Genetics, the study of individual genes, has expanded to include genomics, which is the study of all the

More information

PS02 Biomarker Analysis. Discussant. Sue-Jane Wang, Ph.D.

PS02 Biomarker Analysis. Discussant. Sue-Jane Wang, Ph.D. PS02 Biomarker Analysis Discussant Sue-Jane Wang, Ph.D. Associate Director, Adaptive Design, Pharmacogenomics/Phrmacogenetics Office of Biostatistics, Office of Translational Sciences, CDER CDER Statistics

More information

Introduction to clinical trials

Introduction to clinical trials Introduction to clinical trials Definition of a clinical trial A research activity that involves administration of a test treatment to some experimental unit in order to evaluate the treatment. Key words

More information

ICH Topic E15 Definitions for genomic biomarkers, pharmacogenomics, pharmacogenetics, genomic data and sample coding categories.

ICH Topic E15 Definitions for genomic biomarkers, pharmacogenomics, pharmacogenetics, genomic data and sample coding categories. European Medicines Agency November 2007 EMEA/CHMP/ICH/437986/2006 ICH Topic E15 Definitions for genomic biomarkers, pharmacogenomics, pharmacogenetics, genomic data and sample coding categories Step 5

More information

Pharmacogenetics of Drug-Induced Side Effects

Pharmacogenetics of Drug-Induced Side Effects Pharmacogenetics of Drug-Induced Side Effects Hui - Ching Huang Department of Pharmacy, Yuli Hospital DOH Department of Pharmacology, Tzu Chi University April 20, 2013 Brief history of HGP 1953: DNA

More information

Introduction to Pharmacogenetics Competency

Introduction to Pharmacogenetics Competency Introduction to Pharmacogenetics Competency Updated on 6/2015 Pre-test Question # 1 Pharmacogenetics is the study of how genetic variations affect drug response a) True b) False Pre-test Question # 2 Pharmacogenetic

More information

Personalized Human Genome Sequencing

Personalized Human Genome Sequencing Personalized Human Genome Sequencing Dr. Stefan Platz DABT, Global Head Drug Safety & Metabolism Biomedical research: strengths & limitations of non-animal alternatives 06 December 2016 The Human Genome

More information

First Annual Biomarker Symposium Quest Diagnostics Clinical Trials

First Annual Biomarker Symposium Quest Diagnostics Clinical Trials First Annual Biomarker Symposium Quest Diagnostics Clinical Trials Terry Robins, Ph.D. Director Biomarker R&D and Scientific Affairs Quest Diagnostics Clinical Trials Key Considerations: Biomarker Development

More information

Biomarkers in Clinical Development: Implications for Personalized Medicine and Streamlining R&D in the UK and EU region

Biomarkers in Clinical Development: Implications for Personalized Medicine and Streamlining R&D in the UK and EU region Biomarkers in Clinical Development: Implications for Personalized Medicine and Streamlining R&D in the UK and EU region Dr. Christian Rohlff Oxford Genome Sciences Biomarkers in Clinical Development: Implications

More information

How Targets Are Chosen. Chris Wayman 12 th April 2012

How Targets Are Chosen. Chris Wayman 12 th April 2012 How Targets Are Chosen Chris Wayman 12 th April 2012 A few questions How many ideas does it take to make a medicine? 10 20 20-50 50-100 A few questions How long does it take to bring a product from bench

More information

So, just exactly when will genetics revolutionise medicine? - Part 1

So, just exactly when will genetics revolutionise medicine? - Part 1 So, just exactly when will genetics revolutionise medicine? - Part 1 PRO F. M A RT IN K E N N E DY D EPA RT M ENT O F PAT H O LO GY & C A R N E Y C E N T R E FO R PH A R M ACO GEN O M IC S U N IVERSIT

More information

In Vitro Companion Diagnostic Devices

In Vitro Companion Diagnostic Devices 4 th of Joint Conference of Taiwan and Japan on Medical products regulation In Vitro Companion Diagnostic Devices 2016/12/7 Aoyagi Yumiko Ministry of Health, Labour and Welfare Medical Device Evaluation

More information

REIMAGINING DRUG DEVELOPMENT:

REIMAGINING DRUG DEVELOPMENT: Biology Reconstructed REIMAGINING DRUG DEVELOPMENT: Accurate Disease Modeling To Drive Successful Therapies Julia Kirshner, CEO julia@zpredicta.com 1 SUCCESS RATES OF DRUG DEVELOPMENT ARE LOW, " PARTICULARLY

More information

YOUR FIRST CHOICE FOR IN-OFFICE GENETIC TESTING

YOUR FIRST CHOICE FOR IN-OFFICE GENETIC TESTING YOUR FIRST CHOICE FOR IN-OFFICE GENETIC TESTING THE NEW STANDARD OF CARE WHY GENETIC TESTING? Genetic testing makes it possible to know a priori how your patients will metabolize a specific drug. It is

More information

Integrating pharmacogenetics into national formularies: setting an international research agenda. Dr Howard L McLeod

Integrating pharmacogenetics into national formularies: setting an international research agenda. Dr Howard L McLeod Integrating pharmacogenetics into national formularies: setting an international research agenda Dr Howard L McLeod Professor of Medicine, Genetics, and Pharmacology Washington University, St Louis, USA

More information

Drug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research

Drug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research Drug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research Drug Development Process by which new chemical entities

More information

Comparative Oncology Program

Comparative Oncology Program The Problem: Non-Integrated Cancer Drug Development A Solution: Integration of Informative Non-Clinical Models of Cancer With Clinical Drug Development Efforts Companion Animal Malignancies as Comparative

More information

Pharmacogenomics within the EHR

Pharmacogenomics within the EHR Pharmacogenomics within the EHR Session #258, March 8, 2018 2:30 PM 3:30 PM Jon Walter McKeeby, DSc NIH CC CIO Jharana Tina Patel, PharmD, MBA, Pharmacy Information Officer 1 Conflict of Interest Jon Walter

More information

Introduction to Genomic Medicine Using Galaxy Platform (Workshop)

Introduction to Genomic Medicine Using Galaxy Platform (Workshop) Introduction to Genomic Medicine Using Galaxy Platform (Workshop) INTRODUCTION : Genomics is "an emerging medical discipline that involves using genomic information about an individual as part of their

More information

The experience of Andalusia in ehealth and big data --- Big data in health - IMI s HARMONY project, European Parliament, Brussels, 19 June 2018

The experience of Andalusia in ehealth and big data --- Big data in health - IMI s HARMONY project, European Parliament, Brussels, 19 June 2018 The experience of Andalusia in ehealth and big data --- Big data in health - IMI s HARMONY project, European Parliament, Brussels, 19 June 2018 Joaquín Dopazo Área de Bioinformática, Fundación Progreso

More information

Our website:

Our website: Biomedical Informatics Summer Internship Program (BMI SIP) The Department of Biomedical Informatics hosts an annual internship program each summer which provides high school, undergraduate, and graduate

More information

Personalized Healthcare Diagnostik und Therapie aus einer Hand

Personalized Healthcare Diagnostik und Therapie aus einer Hand Personalized Healthcare Diagnostik und Therapie aus einer Hand Priv.-Doz. Dr. med. Christian Meisel DVFA Life Science Conference, 17 June 2009 1 The Challenge Personalised healthcare Roche s unique position

More information

FDA Regulation of Companion Diagnostics

FDA Regulation of Companion Diagnostics FDA Regulation of Companion Diagnostics Paul Radensky October 11, 2017 Disclosure + Slideset drawn from Part I of presentation made by Janice Hogan, HoganLovells, October 2016 + Updated where appropriate

More information

Personalized Medicine: Will There be a Right Time to Implement?

Personalized Medicine: Will There be a Right Time to Implement? Pharmacogenomics based personalized medicine: Are the standards of evidence requirements different from standards for Clinical-Based Personalized Medicine? Devender S. Dhanda MS MBA, Greg F. Guzauskas

More information

Use of Biomarkers in Drug Development. Janet Woodcock M.D. Director, CDER, FDA

Use of Biomarkers in Drug Development. Janet Woodcock M.D. Director, CDER, FDA Use of Biomarkers in Drug Development Janet Woodcock M.D. Director, CDER, FDA Biomarkers: Extremely Critical to Drug Development Availability of a pharmacodynamic response marker (e.g., viral load) truly

More information

Maximizing opportunities towards achieving clinical success D R U G D I S C O V E R Y. Report Price Publication date

Maximizing opportunities towards achieving clinical success D R U G D I S C O V E R Y. Report Price Publication date F o r a c l e a r e r m a r k e t p e r s p e c t i v e Early Stage Drug Safety Strategies & Risk Management Maximizing opportunities towards achieving clinical success D R U G D I S C O V E R Y Report

More information

The NHS approach to personalised medicine in respiratory disease. Professor Sue Chief Scientific Officer for England

The NHS approach to personalised medicine in respiratory disease. Professor Sue Chief Scientific Officer for England The NHS approach to personalised medicine in respiratory disease Professor Sue Hill @CSOSue Chief Scientific Officer for England Jul 2017 Genomics is probably the biggest breakthrough in the last 50 years.

More information

5 key characteristics

5 key characteristics Biosimilars 5 key characteristics Biologics are medicinal products derived from living organisms. 1 Their use has impacted the treatment of a variety of diseases. 1 Patents for many biologics will soon

More information

Personalized Medicine: What does it mean and why do we want to get there?

Personalized Medicine: What does it mean and why do we want to get there? Personalized Medicine: What does it mean and why do we want to get there? Dan M. Roden MD Assistant Vice Chancellor for Personalized Medicine Principal Investigator, BioVU Vanderbilt University Medical

More information

Vision, aims and strategies. Department of Immunology, Genetics and Pathology Uppsala University

Vision, aims and strategies. Department of Immunology, Genetics and Pathology Uppsala University Vision, aims and strategies Department of Immunology, Genetics and Pathology Uppsala University April19,2011 SCOPEOFACTIVITIESATIGP Research at the Department focuses on translational medicine through

More information

ADVANCES IN PHARMACEUTICAL INDUSTRY FOR WELLNESS AND SUSTAINABLE HEALTH

ADVANCES IN PHARMACEUTICAL INDUSTRY FOR WELLNESS AND SUSTAINABLE HEALTH ADVANCES IN PHARMACEUTICAL INDUSTRY FOR WELLNESS AND SUSTAINABLE HEALTH Faculty of Pharmaceutical Sciences Chulalongkorn University Industrial pharmacy is a discipline which includes manufacturing, development,

More information

Slides are from Level 3 Biology Course Content Day, 7 th November Presenter: Justin O Sullivan

Slides are from Level 3 Biology Course Content Day, 7 th November Presenter: Justin O Sullivan Slides are from Level 3 Biology Course Content Day, 7 th November 2012 Presenter: Justin O Sullivan Teachers are free to use these for teaching purposes with appropriate acknowledgement Personalized genomics

More information

When and how to implement biomarker for cancer care from a French perspective. Fabrice ANDRE Institut Gustave Roussy Villejuif, France

When and how to implement biomarker for cancer care from a French perspective. Fabrice ANDRE Institut Gustave Roussy Villejuif, France When and how to implement biomarker for cancer care from a French perspective Fabrice ANDRE Institut Gustave Roussy Villejuif, France Outline Levels of evidence before implementing a biomarker to the daily

More information

- OMICS IN PERSONALISED MEDICINE

- OMICS IN PERSONALISED MEDICINE SUMMARY REPORT - OMICS IN PERSONALISED MEDICINE Workshop to explore the role of -omics in the development of personalised medicine European Commission, DG Research - Brussels, 29-30 April 2010 Page 2 Summary

More information

Biomarker Regulation. Regulator s perspective. Jan Müller-Berghaus

Biomarker Regulation. Regulator s perspective. Jan Müller-Berghaus www.pei.de Biomarker Regulation Regulator s perspective Jan Müller-Berghaus The views presented here are my own and do not necessarily reflect the views of the Paul-Ehrlich-Institut or any other regulatory

More information

PAREXEL GENOMIC MEDICINE SERVICES. Applying genomics to enhance your drug development journey

PAREXEL GENOMIC MEDICINE SERVICES. Applying genomics to enhance your drug development journey PAREXEL GENOMIC MEDICINE SERVICES Applying genomics to enhance your drug development journey YOUR JOURNEY. OUR MISSION. Genomic expertise to simplify the route to product approval and maximize patient

More information

Drug Targets - an overview of historical success and protein kinase inhibitors - successes and attrition. John P. Overington

Drug Targets - an overview of historical success and protein kinase inhibitors - successes and attrition. John P. Overington Drug Targets - an overview of historical success and protein kinase inhibitors - successes and attrition John P. Overington jpo@ebi.ac.uk Assay/Target ChEMBL The Organisation of Drug Discovery 1. Scientific

More information

Integrating Pharmacogenomics into Decision Making

Integrating Pharmacogenomics into Decision Making Integrating Pharmacogenomics into Decision Making Munir Pirmohamed David Weatherall Chair of Medicine and NHS Chair of Pharmacogenetics Department of Molecular and Clinical Pharmacology Institute of Translational

More information

Personalised medicine towards the market and patients: the approval process

Personalised medicine towards the market and patients: the approval process An agency of the European Union Personalised medicine towards the market and patients: the approval process European Medicines Agency s perspective Presented by: Marisa Papaluca Amati Human Medicines Development

More information

THE ERA OF INDIVIDUAL GENOMES. Sandra Viz Lasheras Advanced Genetics ( )

THE ERA OF INDIVIDUAL GENOMES. Sandra Viz Lasheras Advanced Genetics ( ) THE ERA OF INDIVIDUAL GENOMES Sandra Viz Lasheras Advanced Genetics (2017-2018) CONTENTS 1. INTRODUCTION - The genomic era - Sequencing techniques 2. PROJECTS - 1000 genomes project - Individual genome

More information

Introducing a Highly Integrated Approach to Translational Research: Biomarker Data Management, Data Integration, and Collaboration

Introducing a Highly Integrated Approach to Translational Research: Biomarker Data Management, Data Integration, and Collaboration Introducing a Highly Integrated Approach to Translational Research: Biomarker Data Management, Data Integration, and Collaboration 1 2 Translational Informatics Overview Precision s suite of services is

More information

Molecular Diagnostics

Molecular Diagnostics Molecular Diagnostics Part II: Regulations, Markets & Companies By Prof. K. K. Jain MD, FRACS, FFPM Jain PharmaBiotech Basel, Switzerland May 2018 A Jain PharmaBiotech Report A U T H O R ' S B I O G R

More information

Personalized medicine has been hailed as a

Personalized medicine has been hailed as a 34 Biotechnology Law Report 39 Number 1, 2015 # Mary Ann Liebert, Inc. DOI: 10.1089/blr.2015.9998 The Best Offense Is a Good Defense: Patent Prosecution Strategies During Personalized Medicine Drug Development

More information

Course Agenda. Day One

Course Agenda. Day One Course Agenda BioImmersion: Biotech for the Non-Scientist A three-day, in-depth course that provides the background required for understanding today s fast-paced biotech marketplace. Beginning with an

More information

Biomarkers and clinical trials. Patricia woo UCL

Biomarkers and clinical trials. Patricia woo UCL Biomarkers and clinical trials Patricia woo UCL Definitions Surrogate biomarker: A laboratory or physical sign that is used in therapeutic trials as a substitute for a clinically meaningful endpoint, e.g.

More information

Testimony of Christopher Newton-Cheh, MD, MPH Volunteer for the American Heart Association

Testimony of Christopher Newton-Cheh, MD, MPH Volunteer for the American Heart Association Testimony of Christopher Newton-Cheh, MD, MPH Volunteer for the American Heart Association Before the House Energy and Commerce Subcommittee on Health 21st Century Cures: Examining the Regulation of Laboratory

More information

Les Biomarqueurs: une composante essentielle de la Recherche Translationnelle

Les Biomarqueurs: une composante essentielle de la Recherche Translationnelle Les Biomarqueurs: une composante essentielle de la Recherche Translationnelle Jesús Benavides Ancien Directeur de la Recherche Maladies Neurologiques. Sanofi Ecole Doctorale Biosigne. Université Paris

More information

FDA Perspectives on Biomarkers. Steven Kozlowski, M.D. Office of Biotechnology Products OPS/CDER/FDA

FDA Perspectives on Biomarkers. Steven Kozlowski, M.D. Office of Biotechnology Products OPS/CDER/FDA FDA Perspectives on Biomarkers Steven Kozlowski, M.D. Office of Biotechnology Products OPS/CDER/FDA Importance of Biomarkers Earlier diagnosis Focusing expensive & invasive therapies on the right populations

More information

Reflection paper on co-development of pharmacogenomic biomarkers and Assays in the context of drug development

Reflection paper on co-development of pharmacogenomic biomarkers and Assays in the context of drug development 1 2 3 24 June 2010 EMA/CHMP/641298/2008 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 7 Reflection paper on co-development of pharmacogenomic biomarkers and Assays in the context of drug

More information

Precision Medicine in Sepsis

Precision Medicine in Sepsis Precision Medicine in Sepsis Jean-Daniel Chiche, MD PhD jean-daniel.chiche@aphp.fr MICU & Dept Infection, Immunity & Inflammation Hôpital Cochin & Institut Cochin, Paris-F Sepsis 2017: a litany of failed

More information

The Construction of a Clinical Trial. Lee Ann Lawson MS ARNP CCRC

The Construction of a Clinical Trial. Lee Ann Lawson MS ARNP CCRC The Construction of a Clinical Trial Lee Ann Lawson MS ARNP CCRC 1 Objectives Review Phases of Clinical Research Discuss Orphan Drug Act Discuss regulatory agencies Overview phases of clinical research

More information

Personalized. Health in Canada

Personalized. Health in Canada Personalized Health in Canada Canadian Institutes of Health Research Personalized Medicine Signature Initiative 2010-2013 0 Dr. Morag Park CIHR Institute of Cancer Research Dr. Paul Lasko CIHR Institute

More information

PHYSICIAN RESOURCES MAPPED TO GENOMICS COMPETENCIES AND GAPS IDENTIFIED WITH CURRENT EDUCATIONAL RESOURCES AVAILABLE 06/04/14

PHYSICIAN RESOURCES MAPPED TO GENOMICS COMPETENCIES AND GAPS IDENTIFIED WITH CURRENT EDUCATIONAL RESOURCES AVAILABLE 06/04/14 PHYSICIAN RESOURCES MAPPED TO GENOMICS COMPETENCIES AND GAPS IDENTIFIED WITH CURRENT EDUCATIONAL RESOURCES AVAILABLE 06/04/14 Submitted resources from physician organization representatives were mapped

More information

CENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS: TECHNOLOGIES AND GLOBAL MARKETS

CENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS: TECHNOLOGIES AND GLOBAL MARKETS CENTRAL NERVOUS SYSTEM (CNS) : TECHNOLOGIES AND GLOBAL MARKETS BIO074C March 2016 Jackson Highsmith Project Analyst ISBN: 1-62296-246-X BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215

More information

Personalized CAR-T Immunotherapy Platform

Personalized CAR-T Immunotherapy Platform GLP, GMP, and CLIA-Certified Lab Personalized CAR-T Immunotherapy Platform Accelerate your cancer research and drug discovery Platform Overview 1500 Existing Hybridomas and Antibody Engineering Custom

More information

Preparing For A New Era of Medical Product Development

Preparing For A New Era of Medical Product Development Latham & Watkins Health Care & Life Sciences Practice Number 1607 November 7, 2013 Preparing For A New Era of Medical Product Development FDA report demonstrates support for personalized medicine and more

More information

Successful Academia-Pharma Collaboration Drug Discovery and Clinical Development

Successful Academia-Pharma Collaboration Drug Discovery and Clinical Development Successful Academia-Pharma Collaboration Drug Discovery and Clinical Development Toshio MIYATA Tohoku University Graduate School of Medicine United Centers for Advanced Research and Translational Medicine

More information

Week 1: Discovery Biology Basic knowledge and tools used in Research and Development

Week 1: Discovery Biology Basic knowledge and tools used in Research and Development Downing - Keio Summer School 2018 Healthcare and Biotechnology Course Outline page 1 Strand A: Healthcare and Biotechnology Course Outline This course aims to provide an overview of the current challenges

More information

Applying Affimers. Dr Amanda Nicholl at Avacta Life Sciences. Improving Antibody PK Assay Development

Applying Affimers. Dr Amanda Nicholl at Avacta Life Sciences. Improving Antibody PK Assay Development Improving Pharmacokinetic Assays in a Regulatory Bioanalysis Setting Applying Affimers With an increasing number of antibody-based therapeutics entering the clinic, the need for validated anti-idiotypic

More information

Combination Products Coalition ( CPC ); Points to Consider in Drafting FDA s Co-development Guidance and Other Companion Diagnostic Guidances

Combination Products Coalition ( CPC ); Points to Consider in Drafting FDA s Co-development Guidance and Other Companion Diagnostic Guidances Companion Diagnostics versus Combination Products 1 Under what circumstances is a companion diagnostic a combination product, and when isn t it a combination product? a) If a companion diagnostic is not

More information

The Immunogenicity of Protein Therapeutics: time to get personal?

The Immunogenicity of Protein Therapeutics: time to get personal? The Immunogenicity of Protein Therapeutics: time to get personal? Zuben E Sauna Division of Hematology, Office of Blood Research and Review (OBRR) Center for Biologics Evaluation and Research (CBER) Food

More information

TOWARDS INDIVIDUALIZED MEDICINE: INSIGHTS GAINED FROM GENOMIC STUDIES

TOWARDS INDIVIDUALIZED MEDICINE: INSIGHTS GAINED FROM GENOMIC STUDIES & TOWARDS INDIVIDUALIZED MEDICINE: INSIGHTS GAINED FROM GENOMIC STUDIES Salman Kirmani*, Dusica Babovic-Vuksanovic Department of Medical Genetics, Mayo Clinic College of Medicine, 200 First Street SW,

More information

May 9, Meeting Summary. Facilitating Antibacterial Drug Development

May 9, Meeting Summary. Facilitating Antibacterial Drug Development May 9, 2012 Meeting Summary Facilitating Antibacterial Drug Development Origins of the Current Public Health Crisis of Antibacterial Resistance Antibacterial drugs play a critical role in the ability to

More information

DIAGNOSE AND TREAT WITH ANTIBODIES THAT RECOGNIZE NATIVE HUMAN PROTEIN EPITOPES IN BLOOD AND TISSUE

DIAGNOSE AND TREAT WITH ANTIBODIES THAT RECOGNIZE NATIVE HUMAN PROTEIN EPITOPES IN BLOOD AND TISSUE DIAGNOSE AND TREAT WITH ANTIBODIES THAT RECOGNIZE NATIVE HUMAN PROTEIN EPITOPES IN BLOOD AND TISSUE EXECUTIVE SUMMARY Oncologists reviewing blood and tissue test results face the same problems: Is the

More information

EU support for Health Research from FP6 to FP7

EU support for Health Research from FP6 to FP7 EU support for Health Research from FP6 to FP7 Stéphane Hogan Head of Biotechnology Unit Directorate for Health Research DG Research - European Commission Valencia - 15 September 2006 EU research programmes

More information

Genomics and Proteomics *

Genomics and Proteomics * OpenStax-CNX module: m44558 1 Genomics and Proteomics * OpenStax This work is produced by OpenStax-CNX and licensed under the Creative Commons Attribution License 3.0 By the end of this section, you will

More information

Your story is unique. Diet & Exercise. Environment. Your health. Lifestyle. Genetics A PICTURE OF YOUR HEALTH

Your story is unique. Diet & Exercise. Environment. Your health. Lifestyle. Genetics A PICTURE OF YOUR HEALTH What s your story? Your story is unique It s a complex intersection of where you ve come from, and where your everyday choices are taking you. Optimal health choices for you might be different from others.

More information

BioXplain The Alliance for Integrative Biology The First Open Platform for Iterative, Predictive and Integrative Biology

BioXplain The Alliance for Integrative Biology The First Open Platform for Iterative, Predictive and Integrative Biology The Alliance for Integrative Biology The First Open Platform for Iterative, Predictive and Integrative Biology BioXplain 2009 Pharma R&D critical challenge Despite increasing investments in Technology

More information

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE GUIDELINES INDEX

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE GUIDELINES INDEX INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE GUIDELINES INDEX BATCH Q: Quality Q1A(R2) Stability Testing of New Drug Substances

More information

COPE. FAQs CORPORATE ONCOLOGY PROGRAM FOR EMPLOYEES

COPE. FAQs CORPORATE ONCOLOGY PROGRAM FOR EMPLOYEES COPE CORPORATE ONCOLOGY PROGRAM FOR EMPLOYEES FAQs This brochure addresses FAQ and is prepared solely for the German market. Local adjustments may be necessary. Please contact us if you require additional

More information

Association for Molecular Pathology Promoting Clinical Practice, Basic Research, and Education in Molecular Pathology

Association for Molecular Pathology Promoting Clinical Practice, Basic Research, and Education in Molecular Pathology Association for Molecular Pathology Promoting Clinical Practice, Basic Research, and Education in Molecular Pathology 9650 Rockville Pike, Bethesda, Maryland 20814 Tel: 301-634-7939 Fax: 301-634-7990 Email:

More information

NANOONCOLOGY: DRUG DELIVERY IN NEUROLOGICAL CANCERS. By Ian Kanterman BME281

NANOONCOLOGY: DRUG DELIVERY IN NEUROLOGICAL CANCERS. By Ian Kanterman BME281 NANOONCOLOGY: DRUG DELIVERY IN NEUROLOGICAL CANCERS By Ian Kanterman BME281 Introduction Nanooncology is the application of Nanomedicine to cancer diagnosis and treatment. Has the potential to alter clinical

More information

Controversy In Pharmacogenomics

Controversy In Pharmacogenomics Controversy In Pharmacogenomics Alejandra M. De Jesús-Soto, Mark R. Ruprecht, Patricia Vera-González Principal Investigator: Rafael Irizarry, PhD Graduate Assistant: William Townes, MS Harvard T.H. Chan

More information

Integration of FDSS7000 into a modular robotic system for Open Innovation drug discovery

Integration of FDSS7000 into a modular robotic system for Open Innovation drug discovery Integration of FDSS7000 into a modular robotic system for Open Innovation drug discovery José Manuel Brea & María Isabel Loza BioFarma, Santiago de Compostela DRUG DISCOVERY OPEN INNOVATION CLOSED innovation

More information

ORGANIZATION AND ROLE OF A PHASE I ONCOLOGY UNIT. Dr Philippe CASSIER Centre Léon Bérard, Lyon

ORGANIZATION AND ROLE OF A PHASE I ONCOLOGY UNIT. Dr Philippe CASSIER Centre Léon Bérard, Lyon ORGANIZATION AND ROLE OF A PHASE I ONCOLOGY UNIT Dr Philippe CASSIER Centre Léon Bérard, Lyon Outline Cancer & Oncology Drug development in oncology Specificity of phase I trials in oncology Study design

More information

DNA Studies (Genetic Studies) Disclosure Statement. Definition of Genomics. Outline. Immediate Present and Near Future

DNA Studies (Genetic Studies) Disclosure Statement. Definition of Genomics. Outline. Immediate Present and Near Future Advances in Genetic Marker Evaluation Prior to Vascular Access Creation Timmy Lee, M.D., M.S.P.H., F.A.C.P., F.A.S.N. Assistant Professor of Medicine Division of Nephrology and Hypertension University

More information

Introduction to Bioinformatics

Introduction to Bioinformatics Introduction to Bioinformatics Richard Corbett Canada s Michael Smith Genome Sciences Centre Vancouver, British Columbia June 28, 2017 Our mandate is to advance knowledge about cancer and other diseases

More information

Accelerating Therapeutic Development through a look at current Regulatory Applications A Non-Clinical Perspective

Accelerating Therapeutic Development through a look at current Regulatory Applications A Non-Clinical Perspective Accelerating Therapeutic Development through a look at current Regulatory Applications A Non-Clinical Perspective Imran M. Khan, Ph.D. Division of Psychiatry Center for Drug Evaluation and Research FDA

More information

Using Genomics to Guide Immunosuppression Therapy David A. Baran, MD, FACC, FSCAI System Director, Advanced HF, Transplant and MCS, Sentara Heart

Using Genomics to Guide Immunosuppression Therapy David A. Baran, MD, FACC, FSCAI System Director, Advanced HF, Transplant and MCS, Sentara Heart Using Genomics to Guide Immunosuppression Therapy David A. Baran, MD, FACC, FSCAI System Director, Advanced HF, Transplant and MCS, Sentara Heart Hospital, Norfolk, VA Disclosure Consulting: Livanova,

More information

UNLEASH THE POWER OF PRECISION MEDICINE

UNLEASH THE POWER OF PRECISION MEDICINE FROM BENCH TO BEDSIDE UNLEASH THE POWER OF PRECISION MEDICINE DCB, pioneer in biotech. Your partner in drug discovery. www.dcb.org.tw The Center for Biotechnology With over 400 dedicated researchers and

More information

BIOSTATISTICAL METHODS

BIOSTATISTICAL METHODS BIOSTATISTICAL METHODS FOR TRANSLATIONAL & CLINICAL RESEARCH Phase 0 Trials: EARLY-PHASE CLINICAL TRIALS Steps to New Drug Discovery Get idea for drug target Develop a bioassay Screen chemical compounds

More information

Rare diseases in the 7th EU Framework Programme for Research and Technological Development

Rare diseases in the 7th EU Framework Programme for Research and Technological Development Rare diseases in the 7th EU Framework Programme for Research and Technological Development Manuel Hallen, MD Head of Unit Medical & Public Health Research DG Research European Commission 1 The role of

More information

GENENTECH PROVIDES UPDATE ON PIPELINE AGENTS AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY MEETING

GENENTECH PROVIDES UPDATE ON PIPELINE AGENTS AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY MEETING NEWS RELEASE Media Contact: Krysta Pellegrino (650) 225-8226 Investor Contact: Diane Schrick (650) 225-1599 Advocacy Contact: Kristin Reed (650) 467-9831 GENENTECH PROVIDES UPDATE ON PIPELINE AGENTS AT

More information

BIOSTATISTICAL METHODS FOR TRANSLATIONAL & CLINICAL RESEARCH

BIOSTATISTICAL METHODS FOR TRANSLATIONAL & CLINICAL RESEARCH BIOSTATISTICAL METHODS FOR TRANSLATIONAL & CLINICAL RESEARCH Phase 0 Trials: EARLY-PHASE CLINICAL TRIALS CLINICAL PHASE Clinical Studies: Class of all scientific approaches to evaluate Disease Prevention,

More information

Pharmacogenomics: a long(er) learning curve?

Pharmacogenomics: a long(er) learning curve? Pharmacogenomics: a long(er) learning curve? Hans-Georg Eichler EMA, October 2012 An agency of the European Union Agenda PGx - shades of grey Learning curve/post-marketing evidence development Regulatory

More information

17th EHFG Electing Health The Europe We Want!

17th EHFG Electing Health The Europe We Want! 01 03 October 2014 17th EHFG Electing Health The Europe We Want! For more information about the final programme, speakers or the EHFG conference please contact us directly! Follow us on our social media

More information

Molecular Diagnostics Regulation Shifting from a Biomarker-Based Approach to an Algorithm-Based Approach

Molecular Diagnostics Regulation Shifting from a Biomarker-Based Approach to an Algorithm-Based Approach Molecular Diagnostics Regulation Shifting from a Biomarker-Based Approach to an Algorithm-Based Approach Presented by Kathryn Scheckel Co-authored with Gary Marchant May 27, 2015 Molecular Diagnostics

More information

Specialty Lab Services. Deep science at scale

Specialty Lab Services. Deep science at scale Specialty Lab Services Deep science at scale Advancing biomarker research Our broad expertise and global laboratory footprint deliver deep science at scale Specialty assays drive insight into preclinical

More information

Innovative Medicines Initiative Personalised Medicine Cancer and Diabetic Research. Krakow Biotechnology congress - 13 October 2011

Innovative Medicines Initiative Personalised Medicine Cancer and Diabetic Research. Krakow Biotechnology congress - 13 October 2011 Innovative Medicines Initiative Personalised Medicine Cancer and Diabetic Research Krakow Biotechnology congress - 13 October 2011 Fatiha Sadallah IMI Scientific Manager What is the Innovative Medicines

More information

Human Genome Editing: Science, Ethics, and Governance Highlights for Industry Stakeholders

Human Genome Editing: Science, Ethics, and Governance Highlights for Industry Stakeholders Human Genome Editing: Science, Ethics, and Governance Highlights for Industry Stakeholders Background Advances in genome editing, especially the CRISPR/Cas9 genome editing system, have generated tremendous

More information